Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Apricus Biosciences Inc.

www.apricusbio.com

Latest From Apricus Biosciences Inc.

Forendo Pharma: Tackling The Endometriosis Challenge

Emerging Company Profile: Finland's Forendo Pharma hopes an imminent improvement in diagnostic possibilities will eventually help it commercialize a drug for endometriosis, which it believes could enable more effective treatment of a disease that afflicts large numbers of women.

StartUps and SMEs Gynecology & Urology

Keeping Track Of CRLs: US FDA Again Faults Bausch + Lomb Manufacturing

A look at recent developments tracked by the Complete Response Letters chart on the Pink Sheet's US FDA Performance Tracker.

Complete Response Letters Regulation

Deal Watch: Troubled Antibiotics Maker Cempra Exploring Strategic Options

North Carolina biotech may need to conduct a 9,000-patient safety study after solithromycin was rejected by FDA, but it has $231m in cash and another Phase III candidate. Apricus is clearing financial room by transferring ex-US rights to Vivaros to Ferring, while Heat is acquiring former spinout Pelican.

Deals M & A

Pipeline Watch: Phase III Starts With Durvalumab, Atezolimumab And Eravacycline

Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Topical Delivery
      • Transdermal
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Gynecological, Urological
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • NexMed Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Apricus Biosciences Inc.
  • Senior Management
  • Richard Pascoe, CEO
    Neil C Morton, SVP, CBO.
    Brian T Dorsey, SVP, Chief Dev. Officer
  • Contact Info
  • Apricus Biosciences Inc.
    Phone: (858) 222-8041
    11975 El Camino Real
    Ste. 300
    San Diego, CA 92130
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register